Irinotecan Hydrochloride
Who holds supplier records for Irinotecan Hydrochloride? 18 organisations hold a current record for Irinotecan Hydrochloride: an active US FDA Type II Drug Master File or a CEP. A further 12 organisations have only historical (inactive) DMF filings. 12 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (8), China (5), Finland (1), Taiwan (1) and 1 other country (1); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Irinotecan Hydrochloride: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/irinotecan-hydrochloride
Reading the evidence
- 18 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 11 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (18)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Irinotecan Hydrochloride. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Sun Pharmaceutical Industries LimitedIndia Company GMP cert on recordActive DMF 32675, 20195, 30261 · latest filing Mar 2018
- COHANCE LIFESCIENCES LTDIndiaCEP Company GMP cert on recordActive DMF 43677 · latest filing Mar 2026
- FERMION OYFinlandCEP Company GMP cert on recordActive DMF 20649 · latest filing Jun 2007
- Hetero Labs LimitedIndiaCEP Company GMP cert on recordActive DMF 25686 · latest filing Jan 2012
- Hubei Haosun Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on recordActive DMF 23522 · latest filing Jan 2010
- Laurus Labs LimitedIndiaCEP Company GMP cert on recordActive DMF 22296 · latest filing Nov 2008
- Qilu Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on recordActive DMF 24133 · latest filing Aug 2010
- SCINOPHARM TAIWAN LTDTaiwanCEPActive DMF 17312 · latest filing Apr 2004
- SHILPA PHARMA LIFESCIENCES LTDIndiaCEPActive DMF 23562 · latest filing Feb 2010
- Sichuan Xieli Pharmaceutical Co LtdChinaCEPActive DMF 21713 · latest filing Jun 2008
- ARCH PHARMALABS LTDIndiaActive DMF 24643 · latest filing May 2011
- Emcure Pharmaceuticals LimitedIndia Company GMP cert on recordActive DMF 23220 · latest filing Oct 2009
- JIANGSU HENGRUI PHARMACEUTICALS CO LTDChina Company GMP cert on recordActive DMF 20739 · latest filing Aug 2007
- OLON SPAItaly Company GMP cert on recordActive DMF 21500 · latest filing Mar 2008
- PLIVA-LACHEMA ASActive DMF 19050 · latest filing Dec 2005
- FRESENIUS KABI ONCOLOGY LTDIndiaCEP Company GMP cert on recordInactive DMF 18818 · latest filing Sept 2005
- Jiangsu Xidi Pharmaceuticals Co., LtdChinaCEP
- MAC CHEM PRODUCTS INDIA PVT LTDCEPInactive DMF 26554 · latest filing Sept 2012
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (12)
Certificates of Suitability on the EDQM register for Irinotecan Hydrochloride, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 16 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| LAURUS LABS LIMITED Hyderabad | IN | CEP 2019-292 - Rev 04 Irinotecan hydrochloride trihydrate | Sept 2026 | — |
| JIANGSU XIDI PHARMACEUTICALS CO., LTD Qidong | CN | CEP 2024-311 - Rev 00 Irinotecan hydrochloride trihydrate | Feb 2026 | — |
| SHILPA PHARMA LIFESCIENCES LIMITED Raichur | IN | CEP 2017-147 - Rev 01 Irinotecan hydrochloride trihydrate, Form-b | Jan 2026 | — |
| QILU PHARMACEUTICAL CO., LTD. Jinan | CN | CEP 2016-276 - Rev 02 Irinotecan hydrochloride trihydrate | Sept 2025 | Inspected Feb 2025 Switzerland |
| HETERO LABS LIMITED Hyderabad | IN | CEP 2019-021 - Rev 03 Irinotecan hydrochloride trihydrate, Form-B | Jun 2025 | — |
| COHANCE LIFESCIENCES LIMITED Mumbai | IN | CEP 2023-338 - Rev 00 Irinotecan hydrochloride trihydrate | May 2025 | — |
| MAC CHEM PRODUCTS (INDIA) PVT. LTD. Mumbai | IN | CEP 2018-063 - Rev 02 Irinotecan hydrochloride trihydrate | Nov 2024 | — |
| SCINOPHARM TAIWAN LTD. Shan-Hua | TW | CEP 2017-163 - Rev 01 Irinotecan hydrochloride trihydrate | Sept 2024 | — |
| FRESENIUS KABI ONCOLOGY LIMITED Kalyani | IN | CEP 2017-234 - Rev 03 Irinotecan hydrochloride trihydrate | Apr 2024 | — |
| FERMION OY Espoo | FI | CEP 2017-236 - Rev 02 Irinotecan hydrochloride trihydrate | Sept 2023 | Inspected Feb 2026 Finland |
| SICHUAN XIELI PHARMACEUTICAL CO., LTD. Pengzhou | CN | R1-CEP 2017-096 - Rev 00 Irinotecan hydrochloride trihydrate | Apr 2023 | — |
| HUBEI HAOSUN PHARMACEUTICAL CO., LTD. Ezhou | CN | R0-CEP 2020-025 - Rev 00 Irinotecan hydrochloride trihydrate | May 2022 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (12)
Organisations whose Type II DMFs for Irinotecan Hydrochloride are no longer active. These show a past filing, not current supply.
Show all 12 historical records
- India · Inactive DMF 30516, 25693 · filed Apr 2016
- China · Inactive DMF 27724 · filed Dec 2013
- Zhejiang Charioteer Pharmaceutical Co., Ltd.China · Inactive DMF 24653 · filed Jan 2011
- India · Inactive DMF 23982 · filed Jul 2010
- ALP PHARM BEIJING CO LTDInactive DMF 23949 · filed Jun 2010
- LIANYUNGANG JARI PHARMACEUTICAL CO LTDInactive DMF 21746 · filed Jun 2008
- India · Inactive DMF 20325 · filed Mar 2007
- POLYMED THERAPEUTICS INCInactive DMF 18969, 20223 · filed Jan 2007
- SAI PHYTOCEUTICALS PVT LTDInactive DMF 19661 · filed Jul 2006
- India · Inactive DMF 17456 · filed Jun 2004
- France · Inactive DMF 17348 · filed May 2004
- YAKULT HONSHA CO LTDInactive DMF 8553 · filed May 1990
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Irinotecan Hydrochloride is a topoisomerase inhibitor used in cancer therapy, particularly for colorectal cancer. It works by interfering with the DNA replication process, thereby inhibiting cell proliferation.
Chemical identity
- IUPAC name
- [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;trihydrate;hydrochloride
- Canonical SMILES
- CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.O.O.O.Cl
- InChIKey
- KLEAIHJJLUAXIQ-JDRGBKBRSA-N
- Synonyms
- Camptosar API, campto, camptosar, cpt-11, dq-2805, irinotecan hydrochloride hydrate, irinotecan hydrochloride trihydrate, irinotecan monohydrochloride trihydrate, nsc-759878, onivyde, u-101,440e, u-101440e
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Topoisomerase Inhibitor
- Mechanism of action
- Topoisomerase Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Irinotecan Hydrochloride?
18 organisations hold an active US FDA Type II Drug Master File or a CEP for Irinotecan Hydrochloride: Sun Pharmaceutical Industries Limited (India), COHANCE LIFESCIENCES LTD (India), FERMION OY (Finland), Hetero Labs Limited (India), Hubei Haosun Pharmaceutical Co., Ltd. (China), Laurus Labs Limited (India), Qilu Pharmaceutical Co., Ltd. (China) and SCINOPHARM TAIWAN LTD (Taiwan), and 10 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Irinotecan Hydrochloride Drug Master Files are active?
Sun Pharmaceutical Industries Limited (DMF 32675, 20195), COHANCE LIFESCIENCES LTD (DMF 43677), FERMION OY (DMF 20649), Hetero Labs Limited (DMF 25686), Hubei Haosun Pharmaceutical Co., Ltd. (DMF 23522), Laurus Labs Limited (DMF 22296), Qilu Pharmaceutical Co., Ltd. (DMF 24133) and SCINOPHARM TAIWAN LTD (DMF 17312) and 7 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Irinotecan Hydrochloride records mean?
12 organisations have only inactive Type II DMFs for Irinotecan Hydrochloride. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Irinotecan Hydrochloride have a European Certificate of Suitability?
Yes. 12 organisations hold a valid CEP for Irinotecan Hydrochloride on the EDQM register, including LAURUS LABS LIMITED Hyderabad (IN), JIANGSU XIDI PHARMACEUTICALS CO., LTD Qidong (CN), SHILPA PHARMA LIFESCIENCES LIMITED Raichur (IN), QILU PHARMACEUTICAL CO., LTD. Jinan (CN), HETERO LABS LIMITED Hyderabad (IN) and COHANCE LIFESCIENCES LIMITED Mumbai (IN) and 6 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Irinotecan Hydrochloride supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Irinotecan Hydrochloride?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.